Let me show you something most Americans have completely missed.
In the last few months, four companies quietly stepped before their investors and made announcements that should have stopped the country cold.
Amazon. Google. Meta. Microsoft.
Together, just these four have committed to spending nearly seven hundred billion dollars on technology infrastructure this year alone.
Bloomberg called it "a boom without a parallel this century."
Now here's the part nobody is talking about...
That money doesn't stay with Amazon, Google, Meta, and Microsoft… It drips down.
Every dollar flows through hundreds of smaller technology companies. The ones supplying the chips. The software. The data. The infrastructure.
The little companies trading for just a few dollars right now.
And when that kind of money starts moving through a sector, those small stocks don't just go up.
They explode.
We've seen it before. I know exactly where it's headed this time.
I've put together a free presentation that connects every dot, what's driving this moment, why the window is open right now, and the specific stocks I believe are sitting directly in its path.
Chris Rowe
Bargain Alert: Wells Fargo and Goldman Sachs Look Deeply Oversold
Written by Sam Quirke. Article Published: 3/13/2026.
Key Points
- Shares of Wells Fargo and Goldman Sachs have fallen sharply in recent weeks after disappointing earnings earlier in the year and a broader market shift toward risk-off assets.
- Both stocks are now trading well below recent analyst price targets, which call for meaningful upside from current levels.
- With technical indicators showing extremely oversold conditions and earnings due next month, both banks may be setting up for a recovery rally.
- Special Report: Elon Musk already made me a "wealthy man"
Financial stocks have struggled in recent weeks. Rising geopolitical tensions have rattled global markets and driven investors toward safer assets, while worries about the durability of growth in the banking sector have weighed on financials.
That shift is notable because banks delivered a strong performance for much of 2025. Sentiment can change quickly, however, and two large names hit by the selloff are Wells Fargo & Co (NYSE: WFC) and Goldman Sachs Group Inc (NYSE: GS). Both stocks are down roughly 20% from recent highs and look deeply oversold. Below we examine the potential opportunity in each.
Wells Fargo Looks Extremely Oversold
A massive capital migration is already underway (Ad)
While investors focused on trade war headlines and inflation data, hundreds of billions of dollars were quietly being rerouted into the American technology sector - driven by policy, geopolitics, and an arms race that shows no signs of slowing.
Thirty-year market veteran Chris Rowe says the wealthy are already positioned, and most investors won't recognize the shift until it's too late to act on it.
Watch Chris Rowe's full presentation before it comes downWells Fargo has had a rough start to the year. The stock is down more than 20% since early January and hit fresh lows in mid-March as investors reacted to a mix of company-specific issues and broader market pressure.
Much of the weakness traces back to the bank's most recent earnings report, where Wells Fargo missed expectations on both revenue and earnings, disappointing investors who had come to expect strong results during last year's rally.
The bank also faces operational challenges. Its efficiency ratio remains relatively high compared with peers, which limits the company's ability to expand margins the way investors typically expect from large financial institutions.
Adding to the pressure were reports that Wells Fargo was among several Wall Street lenders with exposure to the failed U.K. mortgage finance firm Market Financial Solutions. While the ultimate financial impact is still unclear, the headline risk exacerbated the selloff.
Is an Opportunity Opening Up?
The sharp decline has left Wells Fargo technically oversold. The stock's relative strength index (RSI) has fallen into deeply oversold territory, a level that often precedes consolidation or a bounce.
Wall Street analysts appear to see the pullback as a buying opportunity. Evercore reiterated its Outperform rating last week, and UBS maintained a Buy rating with a price target near $113 — implying as much as roughly 50% upside from current levels.
For prospective investors, the question is whether Wells Fargo can establish a floor after the recent selloff. If shares begin to stabilize and consolidate in the coming sessions, a recovery rally into next month's earnings could gain momentum.
Goldman Sachs May Also Be Due for a Bounce
Goldman Sachs has seen a similar slide. The stock is down about 20% since January as investors recalibrate expectations after last year's roughly 60% gain.
Part of that pullback also stems from the company's last earnings report, where Goldman missed revenue expectations and raised questions about the resilience of its investment banking and trading businesses in a choppier market.
The bank's valuation has also been scrutinized. Goldman has traded at a premium to many peers, which made it vulnerable when sentiment turned. That drop has pushed the stock into technically oversold territory, with the RSI reaching levels that can signal exhaustion and potential for a rebound.
Why the Market May Be Overreacting
Despite the pullback, analysts remain broadly constructive on Goldman Sachs. JPMorgan recently raised its price target to $826, well above the current trading range around $790, suggesting the market may be undervaluing the stock after the slide. If capital markets activity stabilizes or improves later in the year, Goldman could benefit materially given its leading position in investment banking and trading.
Like Wells Fargo, the key for Goldman is finding a floor. With sector sentiment depressed and technical indicators showing deeply oversold readings, the conditions for consolidation and a relief rally are building.
Next month's earnings reports could serve as catalysts. Don't be surprised if both stocks begin to grind higher ahead of those reports — any signs that growth is stabilizing could help a comeback gather momentum.
Why Boston Scientific's Big Dip Could Be a Bigger Opportunity
Written by Nathan Reiff. Article Published: 3/24/2026.
Key Points
- Boston Scientific shares are down over 25% year-to-date after investors may have been disappointed by the company's 2026 sales guidance.
- Still, there are many positives that could entice investors keen to buy the dip, including strong free cash flow growth and the prospect of access to new markets with the impending completion of the Penumbra acquisition.
- A potential major catalyst for growth is the Champion trial, which could significantly increase the addressable patient pool of Boston Scientific's Watchman line.
- Special Report: Elon Musk already made me a "wealthy man"
Medical device manufacturer Boston Scientific Corp. (NYSE: BSX) has struggled this year, with shares down about 26% year-to-date (YTD) and nearly a third over the past 12 months. But a closer look at the healthcare company's fundamentals shows some solid recent results, including adjusted earnings per share (EPS) of $0.80 for the last quarter, two cents above consensus.
Indeed, a detailed review of Boston Scientific's earnings shows strength in several areas—its electrophysiology (EP) segment, and Watchman devices in particular, have grown rapidly and appear positioned to continue delivering. The company is also expected to release results from its Champion-AF trial by the end of March, which could materially expand the product's addressable patient base. That combination may tempt some investors to buy the dip in BSX stock, but it's important to understand why shares have fallen and what risks remain.
Is the Boston Scientific Dip Justified?
A massive capital migration is already underway (Ad)
While investors focused on trade war headlines and inflation data, hundreds of billions of dollars were quietly being rerouted into the American technology sector - driven by policy, geopolitics, and an arms race that shows no signs of slowing.
Thirty-year market veteran Chris Rowe says the wealthy are already positioned, and most investors won't recognize the shift until it's too late to act on it.
Watch Chris Rowe's full presentation before it comes downShares of BSX dropped after the company's February earnings release, even though revenue rose roughly 16% year over year and adjusted EPS beat expectations. Free cash flow also improved markedly, increasing about 38% year over year to roughly $3.7 billion.
What triggered the selloff? Investors likely focused on Boston Scientific's 2026 organic revenue guidance, which calls for year-over-year growth of 10% to 11%—a meaningful slowdown from 2025's full-year revenue growth of about 20%.
Part of the deceleration stems from the early-2026 discontinuation of certain products in its Axios catheter lineup and other lines.
Management estimates these discontinuations will shave roughly 150 basis points off early-2026 growth.
That said, much of Boston Scientific's business remains intact and continues to grow efficiently. The company has guided to another year of rising free cash flow—about $4.2 billion anticipated in 2026—along with operating margin expansion and improved overall metrics.
The Champion Trial Could Be a Catalyst for Reversal
The results of the Champion trial could help reverse Boston Scientific's recent share weakness. The trial compares the company's Watchman implant for stroke reduction with oral anticoagulation therapy. Investors should watch these results closely, because a positive outcome could expand Watchman's addressable patient pool to roughly 20 million—about four times current estimates.
If Champion is positive, the implications could be significant over multiple years: Boston Scientific would be able to pursue millions of additional patients globally, which could meaningfully accelerate Watchman sales and overall growth.
Another potential growth driver is the planned acquisition of neurovascular device maker Penumbra (NYSE: PEN). Penumbra's products would give Boston Scientific an entry into the mechanical thrombectomy market, where it currently lacks presence. The $14.5 billion deal is partially financed by a $6 billion term loan secured in late February. While that borrowing increases near-term leverage, Boston Scientific's rising free cash flow and strong fundamentals across its core businesses may ease investor concerns.
Risks and Analyst Perspectives Are Worth Keeping in Mind
A negative Champion trial result would be a material risk to Boston Scientific's growth outlook. It would undercut the thesis that Watchman can drive accelerating sales and could make the company's 2026 organic revenue guidance of 10% to 11% harder to achieve.
Still, Wall Street remains largely optimistic. Of 25 analyst ratings, 23 are Buys and two are Holds. Several firms—including Stifel Nicolaus, Jefferies and Truist Financial—reaffirmed Buy ratings in March, though some have trimmed price targets while keeping positive ratings.
The consensus price target of $106.27 implies more than 50% upside from current levels, which helps explain the continued analyst enthusiasm despite recent volatility.
to bring you the latest market-moving news.
This email content is a sponsored message from True Market Insiders, a third-party advertiser of TickerReport and MarketBeat.
Contact Us | Unsubscribe
© 2006-2026 MarketBeat Media, LLC dba TickerReport.
345 North Reid Place, Sixth Floor, Sioux Falls, South Dakota 57103-7078. United States of America..
0 Response to "$700 billion is flowing into one sector. Most people have no idea what that means for them."
Post a Comment